Literature DB >> 3332798

Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections.

R L Tominack1, F G Hayden.   

Abstract

Amantadine and rimantadine are oral antiviral drugs useful in the prophylaxis and treatment of influenza A virus infections. This article reviews the pharmacology, antiviral activity and mechanism of action, pharmacokinetics, toxicities, efficacy, and clinical applications of these agents. When administered in equivalent dosages (200 mg per day), rimantadine has prophylactic efficacy comparable to amantadine but lower potential for causing adverse effects. Despite structural similarities, these drugs differ significantly in their pharmacokinetics, and these differences may account for rimantadine's more favorable toxicity profile. Both drugs provide therapeutic benefit if administered early in uncomplicated influenza, and studies are currently in progress to determine the effectiveness of oral rimantadine in preventing or treating the serious complications of influenza A virus infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3332798

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  25 in total

1.  Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.

Authors:  J Iwahashi; K Tsuji; T Ishibashi; J Kajiwara; Y Imamura; R Mori; K Hara; T Kashiwagi; Y Ohtsu; N Hamada; H Maeda; M Toyoda; T Toyoda
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 2.  Influenza vaccines: present and future.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Amantadine for influenza A.

Authors:  K G Nicholson; M J Wiselka
Journal:  BMJ       Date:  1991-02-23

4.  Comparison of Directigen FLU-A with viral isolation and direct immunofluorescence for the rapid detection and identification of influenza A virus.

Authors:  J L Waner; S J Todd; H Shalaby; P Murphy; L V Wall
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 5.  Influenza.

Authors:  Tom Jefferson
Journal:  BMJ Clin Evid       Date:  2009-03-12

6.  Rapid detection of respiratory syncytial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies.

Authors:  M Waris; T Ziegler; M Kivivirta; O Ruuskanen
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

7.  Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract.

Authors:  R J Fenton; P J Morley; I J Owens; D Gower; S Parry; L Crossman; T Wong
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

8.  Pathogenesis of 1918 pandemic and H5N1 influenza virus infections in a guinea pig model: antiviral potential of exogenous alpha interferon to reduce virus shedding.

Authors:  Neal Van Hoeven; Jessica A Belser; Kristy J Szretter; Hui Zeng; Peter Staeheli; David E Swayne; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

9.  Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice.

Authors:  Huan H Nguyen; Terrence M Tumpey; Hae-Jung Park; Young-Ho Byun; Linh D Tran; Van D Nguyen; Paul E Kilgore; Cecil Czerkinsky; Jacqueline M Katz; Baik Lin Seong; Jae Min Song; Young Bong Kim; Hoa T Do; Tung Nguyen; Cam V Nguyen
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

10.  Multiple-dose pharmacokinetics of rimantadine in elderly adults.

Authors:  R L Tominack; R J Wills; L E Gustavson; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.